[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-cardiomyopathies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-cardiomyopathies":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":40,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100649638","inflammatory-disease-biobank-for-immunophenotyping-and-cardiovascular-research-100649638",false,"NCT07737470","Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research","INFLAMMATORY AND IMMUNE-MEDIATED DISEASES BIOBANKING FOR IMMUNOPHENOTYPING AND CARDIOVASCULAR RESEARCH","INFLAME-BANK","Inclusion Criteria:\n\n* Patient enrolled in EACVI-INFLAME study\n* The patient consents\n\nExclusion Criteria:\n\n* Patients with a history of heart transplant\n* Patient unable to provide informed consent\n* Patient under complete or limited guardianship\n* Patient affected by pre-existing immunodeficiency, including HIV (not including immunosuppressive treatment)","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","INFLAME-BANK is a French multicenter prospective observational ancillary study of the international EACVI-INFLAME project. It aims to establish a biobank and perform immunophenotyping and proteomic analyses in patients with suspected inflammatory cardiovascular diseases and autoimmune rheumatic diseases (ICARDs).\n\nThe primary objective is to identify immune biomarkers associated with cardiovascular prognosis and develop disease-specific prognostic scores to predict 1-year major adverse cardiovascular events (MACE). Secondary objectives include evaluating the diagnostic and prognostic value of immunoproteomic biomarkers, assessing the role of photon-counting CT (PCCT) imaging, and investigating immune signatures associated with genetic variants in acute myocarditis.\n\nThe study plans to enroll 300 patients from French centers participating in EACVI-INFLAME. Blood samples will be collected during routine clinical care at inclusion, with optional follow-up sampling at 12 months and optional PCCT imaging and genetic analyses depending on each center's participation. Patients will be followed for 12 months to monitor cardiovascular outcomes.\n\nThe expected impact is to improve understanding of the immune mechanisms underlying ICARDs, facilitate earlier diagnosis and risk stratification, identify new therapeutic targets, and ultimately support more personalized management of patients with inflammatory cardiovascular diseases.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Pericarditis","Tako-TSUBO Cardiomyopathy","Myocarditis","Inflammatory Cardiomyopathies","Lupus","Systemic Sclerosis","Antiphospholipid Syndrome","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondyloarthritis","ANCA-associated Vasculitis","Takayasu Arteritis","Giant Cell Arteritis","Behçet Disease","Still Disease",[41,42,43,44,45,46,47,48,49,50],"Inflammatory cardiovascular diseases (ICARDs)","Autoimmune rheumatic diseases","Cardiovascular involvement","Immunophenotyping","roteomics","Biomarkers","Biobanking","Major adverse cardiovascular events (MACE)","Cardiovascular imaging","Prospective observational study","NOT_YET_RECRUITING","2026-08-06",{"date":54,"type":55},"2026-08-10","ACTUAL",{"date":57,"type":21},"2026-09-01",{"date":59,"type":21},"2028-10-01",{"name":61,"class":62},"Assistance Publique - Hôpitaux de Paris","OTHER"]